Cambridge, Massachusetts-based Generation Bio, a developer of genetic medicines, has secured $100 million in Series B financing. Fidelity Management & Research Company led the round with participation from Invus, Deerfield Management Company, Casdin Capital, Foresite Capital and Leerink Partners’ affiliates.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: